Literature DB >> 22350157

A case-control study on the effects of the apolipoprotein E genotypes in nonalcoholic fatty liver disease.

Emma De Feo1, Consuelo Cefalo, Dario Arzani, Rosarita Amore, Raffaele Landolfi, Antonio Grieco, Walter Ricciardi, Luca Miele, Stefania Boccia.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) has reached epidemic proportions being the most common cause of chronic liver disease in Western countries. The Apolipoprotein E (ApoE) gene has three major isoforms encoded by the ε2, ε3, and ε4 alleles, with the ε4 allele associated with hypercholesterolemia and the ε2 allele with the opposite effect. The role of apoE genotypes on NAFLD has been previously investigated with conflicting results. Our hospital-based case-control study conducted in Italy aims to explore the effect of the apoE genotypes on NAFLD risk and their effect on the clinical features of NAFLD patients. 310 NAFLD cases and 422 controls were genotyped for apoE. Adjusted odds ratios (ORs) and 95% confidence intervals (CI) from logistic regression were used to explore the relationship between NAFLD and apoE genotypes, as well as their interaction with selected demographic and lifestyle factors. ApoE ε4 allele carriers showed a statistically significant two-fold reduction of NAFLD risk (OR = 0.51, 95% CI: 0.28-0.93) compared with ε3 homozygotes. A statistically significant lower HDL cholesterol level was observed for ApoE ε4 carriers if compared with ε3/ε3 genotype or ApoE ε2 carriers with a nearly linear decreasing trend from ApoE ε2 to ApoE ε4 carriers. Our study reports for the first time a protective effect of the ε4 allele towards NAFLD that might be attributable to its role in the regulation of hepatic triglycerides rich very low-density lipoproteins secretion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22350157     DOI: 10.1007/s11033-012-1570-7

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  28 in total

Review 1.  Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

Authors:  Giovanni Targher; Christopher P Day; Enzo Bonora
Journal:  N Engl J Med       Date:  2010-09-30       Impact factor: 91.245

2.  Simple and effective determination of apolipoprotein E genotypes by positive/negative polymerase chain reaction products.

Authors:  Davide Seripa; Emanuela Signori; Carolina Gravina; Maria Giovanna Matera; Monica Rinaldi; Vito M Fazio
Journal:  Diagn Mol Pathol       Date:  2006-09

Review 3.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

4.  Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease.

Authors:  Mehmet Derya Demirag; Hacer Ilke Onen; Meral Yirmibes Karaoguz; Ibrahim Dogan; Tarkan Karakan; Abdullah Ekmekci; Galip Guz
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

5.  Apolipoprotein E polymorphism modifies the alcohol-HDL association observed in the National Heart, Lung, and Blood Institute Family Heart Study.

Authors:  Luc Djoussé; James S Pankow; Donna K Arnett; John H Eckfeldt; Richard H Myers; R Curtis Ellison
Journal:  Am J Clin Nutr       Date:  2004-12       Impact factor: 7.045

Review 6.  Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Carlos J Pirola
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

7.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

8.  Apolipoprotein e, alcohol consumption, and risk of ischemic stroke: the Framingham Heart Study revisited.

Authors:  Luc Djoussé; Jayandra J Himali; Alexa Beiser; Margaret Kelly-Hayes; Philip A Wolf
Journal:  J Stroke Cerebrovasc Dis       Date:  2009 Sep-Oct       Impact factor: 2.136

9.  A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans.

Authors:  A Kotronen; L E Johansson; L M Johansson; C Roos; J Westerbacka; A Hamsten; R Bergholm; P Arkkila; J Arola; T Kiviluoto; R M Fisher; E Ehrenborg; M Orho-Melander; M Ridderstråle; L Groop; H Yki-Järvinen
Journal:  Diabetologia       Date:  2009-02-18       Impact factor: 10.122

10.  Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene.

Authors:  Konstantinos Kantartzis; Andreas Peter; Fausto Machicao; Jürgen Machann; Silvia Wagner; Ingmar Königsrainer; Alfred Königsrainer; Fritz Schick; Andreas Fritsche; Hans-Ulrich Häring; Norbert Stefan
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  14 in total

Review 1.  Genetic background in nonalcoholic fatty liver disease: A comprehensive review.

Authors:  Fabio Salvatore Macaluso; Marcello Maida; Salvatore Petta
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

2.  A case-control study on the effect of metabolic gene polymorphisms, nutrition, and their interaction on the risk of non-alcoholic fatty liver disease.

Authors:  Luca Miele; Valentina Dall'armi; Consuelo Cefalo; Bojan Nedovic; Dario Arzani; Rosarita Amore; Gianlodovico Rapaccini; Antonio Gasbarrini; Walter Ricciardi; Antonio Grieco; Stefania Boccia
Journal:  Genes Nutr       Date:  2014-01-09       Impact factor: 5.523

3.  Association of apoE gene expression and its gene polymorphism with nephrotic syndrome susceptibility: a meta-analysis of experimental and human studies.

Authors:  Tian-Biao Zhou; Yuan-Han Qin; Hui-Ling Xu
Journal:  Mol Biol Rep       Date:  2012-07-04       Impact factor: 2.316

Review 4.  Early-life enteric infections: relation between chronic systemic inflammation and poor cognition in children.

Authors:  Reinaldo B Oriá; Laura E Murray-Kolb; Rebecca J Scharf; Laura L Pendergast; Dennis R Lang; Glynis L Kolling; Richard L Guerrant
Journal:  Nutr Rev       Date:  2016-05-03       Impact factor: 7.110

5.  Allele-specific variation at APOE increases nonalcoholic fatty liver disease and obesity but decreases risk of Alzheimer's disease and myocardial infarction.

Authors:  Nicholette D Palmer; Bratati Kahali; Annapurna Kuppa; Yanhua Chen; Xiaomeng Du; Mary F Feitosa; Lawrence F Bielak; Jeffrey R O'Connell; Solomon K Musani; Xiuqing Guo; Albert V Smith; Kathleen A Ryan; Gudny Eirksdottir; Matthew A Allison; Donald W Bowden; Matthew J Budoff; J Jeffrey Carr; Yii-Der I Chen; Kent D Taylor; Adolfo Correa; Breland F Crudup; Brian Halligan; Jian Yang; Sharon L R Kardia; Lenore J Launer; Yi-Ping Fu; Thomas H Mosley; Jill M Norris; James G Terry; Christopher J O'Donnell; Jerome I Rotter; Lynne E Wagenknecht; Vilmundur Gudnason; Michael A Province; Patricia A Peyser; Elizabeth K Speliotes
Journal:  Hum Mol Genet       Date:  2021-07-09       Impact factor: 6.150

6.  Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease.

Authors:  Kayleigh L Wood; Michael H Miller; John F Dillon
Journal:  BMJ Open Gastroenterol       Date:  2015-02-17

7.  The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease.

Authors:  Ian James Martins
Journal:  Proteomes       Date:  2016-03-31

8.  Lipoprotein metabolism in nonalcoholic fatty liver disease.

Authors:  Zhenghui Gordon Jiang; Simon C Robson; Zemin Yao
Journal:  J Biomed Res       Date:  2012-12-01

Review 9.  Apolipoprotein E gene variants on the risk of end stage renal disease.

Authors:  Cheng Xue; Wei Nie; Dan Tang; Lujiang Yi; Changlin Mei
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

10.  Global genetic diversity of human apolipoproteins and effects on cardiovascular disease risk.

Authors:  Yitian Zhou; Reedik Mägi; Lili Milani; Volker M Lauschke
Journal:  J Lipid Res       Date:  2018-08-03       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.